Product InnovationOhtuvayre, a first-in-class selective dual inhibitor of PDE3 and PDE4, is the first novel inhaled mechanism for the treatment of COPD in more than 20 years, offering bronchodilator and non-steroidal anti-inflammatory effects.

Revenue GrowthSince its approval and commercial launch, Ohtuvayre has established strong revenue growth, showing a fast adoption among physicians and patients.

Bears Say

Financial PerformanceIncreased costs have been modeled, resulting in a reduction in net income for 2025.

Market PerceptionIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.

Verona Pharma News

Merck completes acquisition of Verona Pharma

Merck (MRK) announced the completion of the Verona Pharma (VRNA) acquisition. Verona Pharma is now a wholly-owned subsidiary...

11d ago

MRK

VRNA

Verona gets England, Wales high court approval for acquisition by Merck

Verona Pharma (VRNA), which entered into a definitive agreement on July 8 relating to its proposed acquisition by...

12d ago

MRK

VRNA

Verona Pharma shareholders approve proposed acquisition by Merck

Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for...

24d ago

MRK

VRNA

Verona Pharma Completes Acquisition and Delisting Process

Verona Pharma ( ($VRNA) ) has shared an announcement. On October 6, 2025, the High Court of Justice...

11d ago

VRNA

Verona Pharma Shareholders Approve Merck Acquisition

Verona Pharma ( ($VRNA) ) has provided an update. On September 24, 2025, Verona Pharma‘s shareholders approved the...

23d ago

VRNA

Verona Pharma Extends Severance Benefits Amid Merck Deal

Verona Pharma ( ($VRNA) ) has issued an announcement. On September 5, 2025, Verona Pharma‘s Board of Directors...

1M ago

VRNA

Verona Pharma’s New COPD Study: What Investors Need to Know

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma is...

2M ago

VRNA

Verona Pharma’s New COPD Study: A Potential Game-Changer?

Verona Pharma (UK) (($GB:VRP)), Verona Pharma (($VRNA)) announced an update on their ongoing clinical study. Verona Pharma has...

2M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

3M ago

VRNA

Verona Pharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from...

3M ago

VRNA

Verona Pharma downgraded to Hold from Buy at Truist

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100,...

3M ago

MRK

VRNA

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK)...

3M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

3M ago

VRNA

Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal

Verona Pharma stock soared on Wednesday after the Ohtuvayre maker announced a $10 billion deal with Merck. ...

3M ago

MRK

VRNA

VRNA FAQ

What was Verona Pharma’s price range in the past 12 months?

Currently, no data Available

What is Verona Pharma’s market cap?

Currently, no data Available

When is Verona Pharma’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Verona Pharma’s earnings last quarter?

Currently, no data Available

Is Verona Pharma overvalued?

According to Wall Street analysts Verona Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Verona Pharma pay dividends?

Verona Pharma does not currently pay dividends.

What is Verona Pharma’s EPS estimate?

Verona Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Verona Pharma have?

Currently, no data Available

What happened to Verona Pharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Verona Pharma?

Currently, no hedge funds are holding shares in VRNA

Company Description

Verona Pharma

Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. The company is primarily involved in the research and development of novel compounds that target unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma's lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to improve lung function and reduce inflammation.